Clinical Trials Logo

Carcinoma, Renal Cell clinical trials

View clinical trials related to Carcinoma, Renal Cell.

Filter by:

NCT ID: NCT00743054 Completed - Clinical trials for Carcinoma, Renal Cell

microRNA Expression in Renal Cell Carcinoma

Start date: July 2008
Phase: N/A
Study type: Observational

In this study, renal cell carcinoma (RCC) related miRNA and the target genes of related miRNA will be examined in order to investigate the role of miRNA in the formation of RCC and look for the biomarker of RCC.

NCT ID: NCT00738530 Completed - Renal Cell Cancer Clinical Trials

A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Start date: June 2004
Phase: Phase 3
Study type: Interventional

This 2-arm study will evaluate the efficacy and safety of Avastin versus placebo in combination with Roferon as first-line treatment in patients with metastatic renal cell cancer (clear cell type) who have had nephrectomy. The anticipated time of study treatment is 1-2 years, and the target sample size is 500+ individuals.

NCT ID: NCT00732914 Completed - Clinical trials for Renal Cell Carcinoma

Sequential Study to Treat Renal Cell Carcinoma

Start date: January 2009
Phase: Phase 3
Study type: Interventional

Primary: To evaluate if progression-free survival from first treatment to progression or death during second-line therapy (total PFS) of sorafenib followed by sunitinib is superior compared to sunitinib followed by sorafenib. Secondary: 1. Time from first treatment to progression during second-line therapy (total TTP) 2. Time to first-line treatment failure (progression, death, discontinuation due to toxicity) descriptively in each arm 3. PFS in first-line and second-line treatment, descriptively 4. Overall survival, descriptively (data cut-off same as for primary endpoint) 5. Disease Control Rate (DCR); Response rates in first-line and in second-line (CR, PR, SD according to RECIST criteria) 6. Cardiotoxicity analysis by means of echocardiography and NT-pro BNP with an interim analysis after 100 patients of each arm have completed the study 7. Safety and tolerability

NCT ID: NCT00731211 Completed - Clinical trials for Renal Cell Carcinoma

Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma

Start date: September 2008
Phase: Phase 2
Study type: Interventional

This is a Phase II, non-randomized, open-label, single-arm study in patients with metastatic renal cell carcinoma who have received one prior targeted therapy with either sunitinib or bevacizumab. The planned enrollment for this study is 60 patients.

NCT ID: NCT00730639 Completed - Clinical trials for Non-small Cell Lung Cancer

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

MDX1106-03
Start date: October 30, 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and effectiveness of MDX-1106 in patients with certain types of cancer. Another purpose is to determine how MDX-1106 is absorbed and distributed within the body, and how it's eventually eliminated.

NCT ID: NCT00729053 Completed - Clinical trials for Renal Cell Carcinoma

Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma

Start date: June 2004
Phase: Phase 2
Study type: Interventional

- Multi-Center - Randomized - Open-Label Study of single agent IMO-2055 - Patients who have Metastatic or Locally Recurrent Clear Cell Renal Carcinoma (RCC)

NCT ID: NCT00726323 Completed - Clinical trials for Carcinoma, Renal Cell

A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)

Start date: June 30, 2006
Phase: Phase 2
Study type: Interventional

This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in papillary renal cell carcinoma. Papillary renal cell carcinoma may be classified into hereditary and sporadic forms; subjects with either classification will be accepted into this study.

NCT ID: NCT00720941 Completed - Clinical trials for Carcinoma, Renal Cell

Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma

COMPARZ
Start date: August 14, 2008
Phase: Phase 3
Study type: Interventional

This study is being conducted to provide a direct comparison of the efficacy, safety and tolerability for pazopanib and sunitinib (SUTENT)

NCT ID: NCT00719264 Completed - Clinical trials for Carcinoma, Renal Cell

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Start date: November 2008
Phase: Phase 2
Study type: Interventional

To estimate the difference in efficacy and safety of bevacizumab and RAD001 compared to bevacizumab and interferon alfa-2a for first-line treatment of patients with metastatic carcinoma of the kidney.

NCT ID: NCT00718367 Completed - Clinical trials for Renal Cell Carcinoma

Correlation of the Clinical Behaviour of Renal Cell Carcinoma (RCC) After Debulking Nephrectomy With Tumor Gene Expression in Nephrectomy Specimens

Start date: March 2008
Phase: N/A
Study type: Observational

The objective of the study is to determine whether a specific immune microenvironment in the primary tumor is associated with a favorable clinical course after nephrectomy and in the absence of adjuvant treatment.